March 2 (Reuters) - Eli Lilly CFO Lucas Montarce

said on Monday it is preparing to launch its new oral obesity

drug, orforglipron, in the United States as early as the second

quarter of this year, once it gets approval from the Food and

Drug Administration.

"On track in the US, expect to see potentially that product

coming into the market as early as Q2," Montarce said at the TD

Cowen healthcare conference.

(Reporting by Kamal Choudhury in Bengaluru)